전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,045 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleBioray LaboratoriesPreclinical

BCMA-UCART (BCMA-UCART)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleHebei Yanda Ludaopei HospitalPhase 1

BCMA/CD19 dual-target CAR-T cell immunotherapy (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

BCMA/CD70-targetd CAR-T (BCMA/CD70-targetd CAR-T)

Juvenile Dermatomyositis (JDM); Polyarticular Juvenile Idiopathic Arthritis · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

BCMA/GPRC5D CAR-T cells (BCMA/GPRC5D CAR-T cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTAAVLimited DatastaleBlackfinBio LtdPhase 2

AAV9-CBh-AP4B1 (BFB-101, BFB-101 (AAV9-CBh-AP4B1))

HSP; Hereditary Spastic Paraplegia · HSP

#HSP#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 1

BHV-1100 plus cytokine induced memory-like (CIML, BHV-1100 plus cytokine induced memory-like, BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 2

Blinatumomab (BLINCYTO, BLINCYTO (Blinatumomab))

Mixed Phenotype Acute Leukemia (MPAL); Measurable Residual Disease (MRD) · Mixed Phenotype Acute Leukemia (MPAL)

#MixedPhenotypeAcuteLeukemiaMPAL#Antibody#Phase2#monoclonal-antibody#MeasurableResidualDiseaseMRD+1
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

OriC321 (BMCA and GPRC5D dual target CAR-T cells, BMCA and GPRC5D dual target CAR-T cells(OriC321))

Multiple Myeloma · GPRC5D

#GPRC5D#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleHighlight TherapeuticsPhase 2

pembrolizumab (Keytruda, BO-112 with pembrolizumab)

Colorectal Cancer; Gastric Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#GastricCancer+1
Trials 1Status Discontinued
CGTLimited DatastaleBioceltech Therapeutics, Ltd.Phase 1

BT-007 CD7 CAR-T cells (BT-007 CD7 CAR-T cells)

T Cell Lymphoblastic Lymphoma · T Cell Lymphoblastic Lymphoma

#TCellLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#monoclonal-antibody#NeuroendocrineTumors+1
Trials 1Status Active
AntibodyLimited DatastaleByondis B.V.Phase 1

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#Byondis
Trials 1Status Recruiting
AntibodyLimited DatastaleYuan YuanPhase 2

Balstilmab (Balstilmab)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase2#monoclonal-antibody#MetastaticTriple-NegativeBreastC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Bamlanivimab (Bamlanivimab)

COVID-19 · COVID-19

#COVID-19#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleBayerPhase 1

BAY1905254 (Bapotulimab, Bapotulimab (BAY1905254))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 1

pembrolizumab (Keytruda, BAY1905254, Bapotulimab, Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active

46 / 103 pages

← PreviousNext →